A study published this month in the journal “Cause and Control of Cancer” found that patients taking metformin had a lower incidence of liver cancer compared with patients taking alternative antidiabetic drugs.
Although other previous studies have found an association between metformin and reduced risk of several cancer types, most studies are affected by multiple factors, such as deviations related to treatment time differences between cases and controls, as well as body mass index and glycemic control And other factors. The researchers in this study strictly controlled these factors in the study of diabetic patients in the National Veterans Health Management Database. They found that the use of metformin was not associated with the incidence of 10 solid tumor types (except liver cancer).
This study suggests that metformin should be further studied clinically, which is expected to achieve the purpose of preventing liver cancer.